Literature DB >> 30227488

Consumers Better Understand and Prefer Simplified Written Drug Information: An Evaluation of 2 Novel Formats Versus the Current CMI.

Julie Aker1, Melissa Beck2, Julie I Papay3, Tom Cantu4, Melissa Ellis3, Dan Keravich5, Kristen Bibeau6.   

Abstract

Patients in the United States receive multiple forms of written drug information with their prescription medicines. This study solicited consumers' preferences about formatting of information, their motivation to read drug information, and their ability to navigate and understand the information. A 3 × 3 study design was used in which 3 prototypes for 3 prescription drugs, ORTHO TRI-CYCLENTM (norgestimate/ethinyl estradiol), COUMADINTM (warfarin sodium), and PARNATETM (tranylcypromine sulfate), were evaluated. The prototypes included 2 novel formats ("new" and "bubble") and the "current" format that patients now commonly receive with their prescriptions. A total of 105 consumers participated in the study. Consumers correctly answered more questions about the medicine when presented with a new (70%-95%) or a bubble prototype (83%-92%) than with the current format (53%-74%). All attributes scored higher with both prototypes compared with the current format. However, in terms of overall preference, consumers favored the new prototype and indicated that they would be more motivated to read it. Consumers also reported that simple icons assisted them in finding important information. The new and bubble prototypes were favored by participants more than the current format. Key attributes preferred by consumers must be considered as new formats for patient medication information are developed.

Entities:  

Keywords:  consumer medication information (CMI); patient medication information (PMI); prescription drug information

Year:  2013        PMID: 30227488     DOI: 10.1177/0092861512462371

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  2 in total

1.  Biennial Analysis of Medication Guide Length and Estimated Readability for New Molecular Entity Drugs, 2011-2017.

Authors:  Paul R Jones; Elisabeth J Walther; Andrew Nguyen; Jonas Santiago; Bryon M Pearsall
Journal:  Ther Innov Regul Sci       Date:  2021-05-10       Impact factor: 1.337

2.  What is the quality of drug safety information for patients: An analysis of REMS educational materials.

Authors:  Hilda W Chan; Andrea M Russell; Meredith Y Smith
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-07-13       Impact factor: 2.890

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.